| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 39,795 | 33,908 | 30,761 | 93,761 |
| Cost of product and license revenue | 4,480 | 3,765 | - | - |
| Research and development | 31,419 | 36,149 | 39,619 | 33,563 |
| Selling, general and administrative | 28,147 | 28,968 | 29,325 | 28,972 |
| Cost of product revenue | - | - | 2,884 | 1,590 |
| Total cost and operating expenses | 64,046 | 68,882 | 71,828 | 64,125 |
| Loss from operations | -24,251 | -34,974 | -41,067 | 29,636 |
| Gain from sale of priority review voucher | 0 | 0 | - | - |
| Investment income, net | 4,559 | 4,671 | 5,094 | 5,322 |
| Other expense, net | -34 | -19 | -23 | 1,197 |
| Total non-operating income, net | 4,525 | 4,652 | 5,071 | 6,519 |
| Loss before income taxes | 19,726 | 30,322 | 35,996 | -36,155 |
| Income tax expense | 0 | 0 | - | -882 |
| Net loss | -19,726 | -30,322 | -35,996 | 37,037 |
| Earnings per share, basic | -0.19 | -0.29 | -0.35 | 0.38 |
| Earnings per share, diluted | -0.19 | -0.29 | -0.35 | 0.38 |
| Weighted average number of shares outstanding, basic | 103,381,315 | 103,069,154 | 102,710,382 | 96,623,123 |
| Weighted average number of shares outstanding, diluted | 103,381,315 | 103,069,154 | 102,710,382 | 96,937,759 |
Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals, Inc. (DAWN)